Introduction
============

Globally, topiramate is approved in children and adults for at least one indication including adjunctive and monotherapy treatment of partial onset seizures and primary generalized tonic--clonic seizures as well as adjunctive treatment of seizures associated with Lennox--Gastaut syndrome, and in adolescents and adults for migraine prophylaxis.[@b1-opth-11-983]

The precise mechanisms by which topiramate, a sulfamate-substituted mono-saccharide, exerts its antiseizure and migraine prophylactic effects are unknown. Results from electrophysiological and biochemical studies on cultured neurons have suggested three properties that may contribute to the antiepileptic efficacy of topiramate: sodium channel blocking action, potentiation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), and antagonism of the kainate/a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) subtype of the excitatory amino acid glutamate receptor.[@b2-opth-11-983] GABA is a more potent modulator in the retina and GABA potentiation is the mechanism of action (MOA) of several antiepileptic drugs (AEDs) including vigabatrin and pregabalin.[@b3-opth-11-983]--[@b6-opth-11-983]

Visual field defects (VFDs) can manifest as scotoma, both homonymous and heteronymous hemianopia, and peripheral vision loss or tunnel vision.[@b7-opth-11-983] A variety of ophthalmologic treatment-emergent adverse events (TEAEs) have been reported with topiramate use, including acute angle-closure glaucoma, maculopathy, ciliochoroidal detachment, ciliary body edema, and acute myopic shift, some of which are associated with VFDs.[@b1-opth-11-983],[@b8-opth-11-983]--[@b10-opth-11-983] These TEAEs suggest that topiramate therapy has the potential to cause VFDs. Preclinical findings in topiramate-treated rabbits suggest that topiramate may damage the retina, similar to vigabatrin.[@b11-opth-11-983] In humans, \~30% of adult patients exposed to vigabatrin have reported some degree of VFDs that are irreversible.[@b12-opth-11-983],[@b13-opth-11-983] This study was aimed to determine the possible MOA for VFDs reported with topiramate treatment and to comprehensively analyze clinical patterns including type of VFDs, risk factors for their development, relationship to topiramate dose and duration of therapy, and persistence of VFDs.

Methods
=======

Literature search
-----------------

A search and review of the cases from the global safety database (SCEPTRE) was carried out for only spontaneous cases. No formal literature review was conducted and reviewed in this report. However, cases reported from the literature may have been included in the SCEPTRE if the Center of Excellence identified the published literature in their searches.

Valid, spontaneous, medically confirmed or not confirmed cases with topiramate as suspect or suspect-interacting drug (highest version in date range) received cumulatively through May 31, 2013, were included in the review. Cases that were in workflow at the time of the database search were not captured as part of this search. Also, adverse events were coded to the preferred terms (PTs) included in the Medical Dictionary for Regulatory Activities (MedDRA, version 16.0).

All cases were retrieved independent of the reporter's relationship attribution, and all spontaneous cases were considered possibly related at the time of entry into the database. Therefore, individual assessments may not be in agreement with the causality assessment of the reporter.

Comparison with other GABA-ergic medications
--------------------------------------------

Pregabalin and vigabatrin have a GABA-ergic MOA and are associated with VFDs. Topiramate has a similar MOA. Thus, the MOA of topiramate, pregabalin, and vigabatrin, and its association with VFDs were reviewed based on a search of the medical literature. Differences in how these three drugs inhibit GABA signaling may still account for differences in their adverse event profiles. VFDs were defined as TEAEs coded to PTs included in MedDRA (version 14.0) high level term visual field disorders ([Table S1](#SD1-opth-11-983){ref-type="supplementary-material"}).

Concern about a possible association of topiramate therapy with VFDs and its possible relationship to a significant reduction of retinal function appears to arise, at least partly, from a study by Kjellström et al.[@b11-opth-11-983] Other studies have further examined the effects of vigabatrin, pregabalin, and topiramate on cerebral and retinal GABA levels in animal models. A formal literature search was conducted to identify animal studies.

Preclinical evidence that explored topiramate's effects on visual function was summarized from animal studies, including topiramate's effects on retinal function and histopathology in rabbits;[@b11-opth-11-983] effects of gabapentin, vigabatrin, and topiramate in rats;[@b5-opth-11-983] topiramate in an excitotoxin-induced neurotoxicity model that used two different retinal primary cultures, and a rat model of retinal ischemic injury.[@b14-opth-11-983] A clinical study (healthy volunteers) assessing the effect of topiramate, lamotrigine, and gabapentin on cerebral GABA levels was also reviewed.[@b3-opth-11-983]

A comprehensive retrospective data review included analysis of all Janssen R&D sponsored data from double-blind, placebo-controlled trials (DBPCTs) and open-label trials (OLTs) in approved and investigational indications for topiramate, and postmarketing spontaneous reports (Janssen R&D safety database). In addition, the medical literature for AEDs (cutoff date: April 2015) was reviewed.

Comprehensive retrospective review of clinical trial data
---------------------------------------------------------

All Janssen R&D-sponsored trials for topiramate in approved and investigational indications reviewed for this analysis were approved indications: adjunctive treatment of epilepsy (DBPCTs =17, OLTs =30), monotherapy treatment of epilepsy (DBPCTs =5, OLTs =3), and migraine prophylaxis (DBPCTs =13, OLTs =8); investigational indications: bipolar disorder (DBPCTs =7, OLTs =5), essential tremor (DBPCTs =1, OLTs =1), binge eating disorder (DBPCTs =2, OLTs =1), diabetic peripheral neuropathy (DBPCTs =5, OLTs =4), obesity (DBPCTs =11, OLTs =1), alcohol dependency (DBPCTs =1), and cognitive function (observer-blinded trial =1).

Spontaneous postmarketing reports from Janssen R&D safety database
------------------------------------------------------------------

All spontaneously reported postmarketing cases (July 1995 to April 2015) of visual symptoms possibly associated with retinal dysfunction were reviewed in topiramate-treated patients. The Global Medical Safety database, Strategic Clinical and Epidemiological Pharmacovigilance Technology for Risk Evaluation were searched for all medically confirmed and consumer reported cases, using prespecified MedDRA high level terms or system-organ class or both.

Data analysis
-------------

The search terms used for TEAEs suggestive of retinal dysfunction or damage were PTs coded using MedDRA (version 14.0). For DBPCTs, TEAEs were summarized for each indication separately and for all doses combined (for patients randomized to topiramate and placebo, but not to active controls). For studies with only flexible doses of topiramate and without fixed dose groups, all topiramate-treated patients were combined in one group and the actual administered dose range was indicated. All randomized patients who took at least one dose of topiramate or placebo were included in the summaries. For OLTs, TEAEs were summarized for all topiramate-treated patients by indication, combining all doses. Patients randomized to an active comparator medication during the double-blind (DB) phase, but who were switched to topiramate during the open-label (OL) phase, were added to the topiramate group. Relative risk (RR) was calculated for the DBPCTs using a derived dataset which included, from each study, the number of patients on topiramate and placebo, and the number of patients with retinal-related TEAEs per treatment group. All spontaneously reported postmarketing cases that included topiramate, identified as either a suspect including co-suspect, suspect-interacting, or concomitant medication were retrieved, independent of the reporter's relationship attribution. There were too few patients per dose category to allow for stratification by dose analysis.

Studies were combined by treatment group (topiramate or placebo). The proportions and RR were then calculated based on a 2×2 table that resulted from the pooled dataset. The *P*-value was calculated based on a chi-square test. RR, its standard error, and 95% confidence interval were calculated according to Altman.[@b15-opth-11-983]

Results
=======

Relationship of GABA-ergic MOA to VFDs
--------------------------------------

### Human studies

Topiramate, vigabatrin, and pregabalin share a GABA-ergic component in their MOA. Furthermore, other drugs (barbiturates, benzodiazepines, and tiagabine) with a GABA-ergic component in their MOA do not affect retinal function in humans.[@b16-opth-11-983]--[@b18-opth-11-983] Cerebral GABA levels were elevated in healthy adults treated with topiramate, lamotrigine, or gabapentin; however, no correlation with VFDs was observed.[@b5-opth-11-983]

### Animal studies

Retinal immunohistology revealed significant accumulation of GABA in amacrine cells in the inner nuclear layer and in the inner plexiform layer in 4 of 6 topiramate-treated rabbits, compared with controls.[@b11-opth-11-983] However, serum topiramate levels in these rabbits (6.4--15.8 μmol/L) were comparatively lower than in patients with refractory focal epilepsy (6--56 μmol/L), who did not demonstrate any dose-related VFDs;[@b19-opth-11-983] results seemed to be affected by the poor tolerability of topiramate in rabbits.

In rats (N=110) treated with vigabatrin, topiramate, or gabapentin, retinal GABA concentrations were significantly increased with vigabatrin, but not with topiramate or gabapentin treatment;[@b5-opth-11-983] results suggesting important differences among these drugs on retinal GABA metabolism. Topiramate decreased the excitotoxin-induced neurotoxicity of glutamate or AMPA in a concentration-dependent manner in retinal or retinal ganglion cell cultures.[@b14-opth-11-983] In a rat model, topiramate reduced the ischemia-induced decrease in the amplitude of the electroretinogram b-waves 3 days after ischemia and ischemia-induced retinal degenerative changes.

These data from both human and animal studies suggest that retinal toxicity is not a class-specific TEAE in GABA-ergic AEDs, but rather significant variation exists within this class. Overall, this review of AEDs associated with VFDs suggested that VFDs were not a class effect for drugs having a GABA-ergic component in their MOA.

Comprehensive retrospective review of clinical trial data
---------------------------------------------------------

### Trials in approved indications

Across these trials, topiramate DB exposure for patients was up to 16 weeks, and OL phase median exposure was approximately 1 year.

#### DBPCTs (NCT00231556; NCT00236639; NCT00231530; NCT00236730; NCT00236691)

The incidence of TEAEs suggestive of retinal dysfunction or damage was higher among topiramate-treated patients (N=4,679; ranging from 0.3% to 0.7% for all topiramate doses combined) compared with placebo-treated patients (N=1,834; ≤0.1%, retinal tear in one patient in the migraine prophylaxis indication) ([Table 1](#t1-opth-11-983){ref-type="table"}). The most commonly reported TEAEs among topiramate-treated patients were VFDs (0.3% in each indication) and scotoma (\<0.1% to 0.4% across indications); TEAEs occurred in the dose range, 50--1,000 mg/day. All events were mild or moderate in severity with no serious TEAEs. Treatment limiting VFDs occurred in 2 patients (migraine prophylaxis indication), which led to permanent discontinuation of the study drug in 1 patient, and dose reduction in the other (VFDs resolved in both).

#### OLTs

The incidence of TEAEs suggestive of retinal dysfunction or damage ranged from 0.3% (7/2,750) in migraine studies to 0.7% in monotherapy epilepsy studies (all topiramate doses combined) ([Table 1](#t1-opth-11-983){ref-type="table"}). For migraine studies, this included patients who received placebo during the DB phase, but who switched to topiramate in the OL phase. The majority of TEAEs reported in topiramate-treated patients were VFDs (all indications: 0.1%--0.4%), scotoma (migraine prophylaxis and monotherapy epilepsy: \<0.1% to 0.4%), and optic atrophy (adjunctive epilepsy: 0.2%). Optic atrophy TEAEs were all reported for patients receiving adjunctive topiramate treatment for epilepsy, who were also concomitantly receiving valproate, another AED that has been associated with VFDs.[@b18-opth-11-983],[@b20-opth-11-983],[@b21-opth-11-983] Most of the TEAEs were mild or moder ate in severity; the majority resolved. Few TEAEs were serious: retinal hemorrhage in 1 patient in monotherapy epilepsy indication (resolved) and occlusion of retinal vein in 1 patient in migraine prophylaxis indication (persisted). In topiramate-treated patients, the study drug was discontinued in 4 patients (VFD, tunnel vision, retinal hemorrhage, and occlusion of retinal vein, N=1 in each; all 3 events except retinal vein occlusion resolved), and dose was adjusted in 1 patient (optic atrophy).

### Trials in investigational indications

#### DBPCTs

The incidence of TEAEs suggestive of retinal dysfunction or damage ranged from 0% to 0.8% among topiramate-treated patients, compared with 0%--1.1% among placebo-treated patients ([Table 2](#t2-opth-11-983){ref-type="table"}). This is based on TEAEs suggestive of retinal damage reported in investigational indication studies. The most commonly reported TEAE was VFD (0.1%--0.5% in all indications; none serious). These events occurred in patients treated with topiramate in a dose range of \<100--600 mg/day. Three events from studies conducted for an obesity indication were treatment limiting: two patients discontinued the study drug (tunnel vision, events resolved) while one patient had a dose reduction (retinal hemorrhage). In the placebo-treated patients, the most frequent adverse event was retinal hemorrhage.

#### OLTs

The incidence of TEAEs suggestive of retinal dysfunction or damage in the OLTs was \<0.1% except for the diabetic peripheral neuropathy indication (1.4%) ([Table 2](#t2-opth-11-983){ref-type="table"}). The most commonly reported events among topiramate-treated patients (including those receiving placebo during the DB phase who switched to topiramate during OL) were retinopathy (0.6%), retinal hemorrhage (0.3%), and retinal detachment (0.2%), all in the diabetic neuropathy indication. Only one serious event of retinal detachment (diabetic neuropathy indication) was reported. One TEAE that was treatment limiting (retinal detachment) resolved after the study drug was temporarily discontinued.

RR analysis
-----------

Only DBPCTs in both approved and investigational indications were included in the RR analysis, for which all topiramate dose groups and events were combined due to sparse data. The incidence of events in the topiramate group (0.36%) was not significantly different from that in the placebo group (0.24%; RR of topiramate vs placebo treatment 1.51; 95% confidence interval: 0.78, 2.91) ([Figure 1](#f1-opth-11-983){ref-type="fig"}).

Spontaneous postmarketing reports
---------------------------------

From July 1995 to April 2015, 96 spontaneous postmarketing reports of visual field disorders in topiramate-treated patients were retrieved, which included VFDs (N=89), tunnel vision (N=11), scotoma (N=6), hemianopia homonymous (N=4), and hemianopia (N=3). The largest number of cases occurred in the 36--50 age group and women. VFDs were considered serious in 68% of the overall cases ([Table 3](#t3-opth-11-983){ref-type="table"}). The latency of the cases was variable, ranging from a few hours up to 10 years. Of the 96 case reports, 75 were excluded by case-level review, because of poor documentation (N=42), not confirmed medically (N=15), or confounded by concomitant disease or medication (N=18). The remaining 21 reports included 14 cases that were confirmed medically and 7 cases that were not. Of the 14 medically confirmed cases, 13 cases (2 were duplicates, hence only one was retained) reported a plausible temporal relationship between exposure to the drug and the TEAE, 9 cases reported a positive dechallenge, and 1 case reported a positive rechallenge. Based on the overall reporting rate in the Global Medical Safety worldwide safety database, VFDs occur at a rate of 1 per 118,339 person-years, and the assigned Council for International Organizations of Medical Sciences frequency category was "very rare."

Case reporting positive rechallenge
-----------------------------------

The patient experienced depression and visual scotoma 22 days after initiating topiramate therapy. Two months later, the dose was decreased from 50 to 25 mg daily. Due to persistence of symptoms, therapy was withdrawn 2 months later. Approximately 1 month after stopping therapy, topiramate was restarted at 25 mg daily and after some days, the patient again experienced the same symptoms.

### Marketing authorization holder comment

The close temporal relationship between initiation of therapy and onset of the adverse event, continuation of the event during therapy, and the reappearance of symptoms when the patient was readministered topiramate suggest a relationship between the therapy and events. No ophthalmologic evaluation was provided to determine the nature and extent of the scotoma and to establish the similarity of the original event and that of the rechallenge.

Discussion
==========

This comprehensive review examined the relationship between topiramate therapy and VFD ophthalmologic disorders by comparing its MOA in preclinical studies and available medical literature with other AEDs associated with VFD and assessed the sponsor's clinical database and postmarketing spontaneous reports for topiramate-related VFDs.

The similarity in MOA of topiramate to other AEDs, for example, vigabatrin and pregabalin, which are associated with increased VFDs, suggested that VFDs may be a class effect.[@b22-opth-11-983],[@b23-opth-11-983] In particular, the GABA-ergic MOA of these AEDs is responsible for elevated GABA levels in the retina, which leads to retinal damage. However, it was found that other AEDs (eg, benzodiazepines, felbamate, levetiracetam, gabapentin, tiagabine, etc) with a GABA-ergic MOA are not associated with visual disorders, which suggests that VFDs are not a class effect for drugs with this MOA.[@b17-opth-11-983],[@b18-opth-11-983],[@b22-opth-11-983] The VFDs linked to vigabatrin therapy are related to dysfunction of GABA-ergic cells of the inner retina, which could be the primary target for toxic injury.[@b24-opth-11-983] Clinically, vigabatrin has been associated with permanent VFDs characterized by concentrically constricted fields.[@b12-opth-11-983],[@b13-opth-11-983] In contrast, topiramate has shown retinal protective properties in excitotoxin-induced neurotoxicity models.[@b14-opth-11-983] Topiramate has been associated with acute myopia which is associated with secondary angle-closure glaucoma, primarily due to drug-induced idiosyncratic ocular syndrome in reaction to the sulfamate moiety of topiramate, similar to that seen with other sulfa containing medications such as sulfamethizole, chlorthalidone, ethoxzolamide, hydrochlorothiazide, sulfapyridine, trimethoprim, and acetazolamide.[@b25-opth-11-983]--[@b27-opth-11-983] Although this phenomenon is not completely understood, it is suggested that it could be caused by ciliary body swelling resulting in anterior movement of the lens, and by lens thickening.[@b28-opth-11-983]

This review of the product sponsor's clinical trials database showed that while the drug exposure in OLTs was generally longer, the incidence of TEAEs suggestive of retinal dysfunction or damage with topiramate therapy in DBPCTs was similar to the OLTs for both approved and investigational indications. This suggests that increased dosing duration did not confer increased risk of VFDs. In addition, the VFDs in this study occurred following topiramate doses ranging from 50 to 1,000 mg/day, which is similar to the reports in literature, suggesting that the severity of VFDs does not correlate with higher doses.[@b29-opth-11-983],[@b30-opth-11-983] In a case report, angle-closure glaucoma was reported in a patient with topiramate plasma levels that were lower than the therapeutic level.[@b31-opth-11-983] A limitation of this current review is that precise information of TEAEs and a dose--response relationship could not be determined. Thus, findings from the clinical trials in this study, and literature, suggest that the idiosyncrasy (unusual or odd behavior of person) hypothesis for topiramate-induced VFDs may be a possibility. Although the authors searched databases that included literature referencing, they did not conduct a formal literature review in the Embase and Medline search engines, and may thus have missed a limited number of additional reports.

For approved indications in children and adults, there was a higher incidence among epilepsy patients compared with migraine patients. For epilepsy patients, those treated with adjunctive topiramate had a higher incidence of VFD compared to monotherapy topiramate. However, the latter were also receiving concomitant AEDs, carbamazepine, valproate, gabapentin, and vigabatrin that are associated with visual disorders.[@b22-opth-11-983] It should also be considered that symptoms of aura can also occur in migraine or epilepsy. It is noteworthy that, compared to the general population, patients with epilepsy or migraine have a higher incidence of visual disturbances. In adult and pediatric patients with migraine treated with topiramate ([Table 1](#t1-opth-11-983){ref-type="table"}), VFDs associated with topiramate therapy could be misdiagnosed as a migraine attack, and the patient could be treated with higher doses of topiramate, which could further aggravate the problem.[@b32-opth-11-983]

In diabetic peripheral neuropathy DBPCTs, retinal hemorrhage was reported in a higher percentage of patients treated with placebo than in topiramate-treated patients. In the OLTs for investigational indications, all but one treatment-limiting adverse event was reported in patients from diabetic peripheral neuropathy studies, a population that is more prone to developing vision complications. This reiterates the fact that the underlying disease could be a potential confounder. Diabetic retinopathy is the leading cause of vision loss in adults of working age (20--65 years) in industrialized countries, and it is estimated that \>2.5 million people worldwide are affected by it.[@b10-opth-11-983]

In addition, the statistical analysis based on several DBPCTs (approved and investigational indications) comparing the occurrence of VFDs following topiramate and placebo treatment demonstrated that the RRs of VFDs were not significantly different for both. Few events were serious and treatment limiting, and most were reversible. Resolution of VFD symptoms upon discontinuation of topiramate has been reported in the literature.[@b8-opth-11-983],[@b9-opth-11-983],[@b33-opth-11-983],[@b34-opth-11-983]

The review of cumulative postmarketing reports involving TEAEs of VFDs with topiramate treatment that was conducted for this current analysis showed that the majority of patients were adults (despite inclusion of both adults and children) and women. Although women have a marginally lower incidence of epilepsy than men, topiramate's other approved indication, migraine, occurs more frequently in women, with a ratio of 2.3:1 (women:men).[@b35-opth-11-983],[@b36-opth-11-983] In patients where latency was reported, three-fourths developed VFDs within 6 months of treatment initiation. A rechallenge in VFD was conducted to decipher the underlying mechanisms for TEAEs induced by the drug and was confirmed only in one patient. Thus, medically confirmed TEAEs of VFD that suggest a relationship between topiramate and VFDs as evaluated on the basis of temporal relationship, positive dechallenge or rechallenge, or presence of confounders were rare, and the majority were reversible.

One of the strengths of this study was that the results are based on a comprehensive and large database of patients, including randomized DBPCTs and long-term OLTs, in which safety during longer exposure periods was obtained. The occurrence of postmarketing reports of VFDs, including scotoma and maculopathy, was rare. Based on this comprehensive review of preclinical, clinical, and postmarketing information, ophthalmological TEAEs, including VFDs, do not appear to be a class effect for AEDs with similar GABA-ergic components in their MOA. A comprehensive review of topiramate data revealed a slightly increased incidence of visual TEAEs in topiramate-treated versus placebo-treated patients. However, RR assessment was found to be not significant, and thus clinical relevance of such risks cannot be ascribed to topiramate therapy. Warnings indicate that if any ophthalmologic event, symptom, or sign persists on examination during topiramate treatment, an evaluation by the prescribing physician would be required, which appears to be consistent with the level of risk identified in this study. Given topiramate's documented effectiveness for the approved therapeutic indications,[@b19-opth-11-983],[@b37-opth-11-983]--[@b39-opth-11-983] the overall benefit--risk balance for its use, as indicated, remains favorable.

Supplementary material
======================

###### 

MedDRA (version 14.0) preferred terms suggestive of retinal dysfunction or damage

  ------------------------------------------ -----------------------------------
  Macular cyst                               Macular ischemia
  Macular degeneration                       Venous stasis retinopathy
  Age-related macular degeneration           Biopsy conjunctiva
  Macular opacity                            Biopsy conjunctiva abnormal
  Maculopathy                                Biopsy conjunctiva normal
  Vitreous adhesions                         Biopsy cornea
  Pars plana cyst                            Biopsy cornea abnormal
  Retinal cyst                               Biopsy cornea normal
  Retinal degeneration                       Biopsy retina
  Retinal depigmentation                     Biopsy retina abnormal
  Retinal degeneration                       Biopsy retina normal
  Retinal deposits                           Biopsy sclera
  Retinal detachment                         Biopsy sclera abnormal
  Retinal dystrophy                          Biopsy sclera normal
  Retinal pallor                             Fundoscopy
  Retinal pigment epitheliopathy             Fundoscopy abnormal
  Retinal pigmentation                       Fundoscopy normal
  Retinal scar                               Gonioscopy
  Retinal tear                               Gonioscopy abnormal
  Retinopathy solar                          Gonioscopy normal
  Retinoschisis congenital                   Paracentesis eye
  Retinal toxicity                           Paracentesis eye abnormal
  Macular hole                               Paracentesis eye normal
  Osteoporosis-pseudoglioma syndrome         Retinogram
  Detachment of retinal pigment epithelium   Retinogram normal
  Retinal pigment epithelial tear            Retinogram abnormal
  Acquired pigmented retinopathy             Visual field tests
  Laurence--Moon--Bardet--Biedl syndrome     Visual field tests abnormal
  Macular pseudohole                         Visual field tests normal
  Retinoschisis                              Optic nerve disorder
  Subretinal fibrosis                        Optic neuropathy
  Macular scar                               Toxic optic neuropathy
  Retinal infiltrates                        Visual pathway disorder
  Chorioretinitis                            Visual evoked potentials
  Choroid tubercles                          Visual evoked potentials abnormal
  Choroiditis                                Visual evoked potentials normal
  Diabetic retinal edema                     Blindness
  Macular edema                              Chorioretinal atrophy
  Cystoid macular edema                      Chorioretinal scar
  Retinal edema                              Chorioretinopathy
  Retinal vasculitis                         Choroidal detachment
  Retinitis                                  Choroidal effusion
  Retinitis viral                            Choroidal hematoma
  Toxocariasis                               Choroidal hemorrhage
  Vitreous abscess                           Choroidal infarction
  Vitritis                                   Choroidal neovascularization
  Necrotizing retinitis                      Choroidal sclerosis
  Hemianopia                                 Exudative retinopathy
  Hemianopia heteronymous                    Optic atrophy
  Hemianopia homonymous                      Optic disc disorder
  Scotoma                                    Optic disc drusen
  Tunnel vision                              Optic nerve cupping
  Visual field defect                        Papillophlebitis
  Uhthoff 's phenomenon                      Retinal artery embolism
  Macular vasospasm                          Retinal artery occlusion
  Optic ischemic neuropathy                  Retinal artery thrombosis
  Optic nerve infarction                     Retinal disorder
  Retinal artery spasm                       Retinal exudates
  Retinal artery stenosis                    Retinal neovascularization
  Retinal ischemia                           Retinal vascular disorder
  Retinal hemorrhage                         Retinal vascular thrombosis
  Retinal vein thrombosis                    Retinopathy
  Retinal vein occlusion                     Venous stasis retinopathy
  Retinal vascular occlusion                 Vitreous hemorrhage
  Retinal infarction                         
  ------------------------------------------ -----------------------------------

Dr Sangita P Patil and Dr Vaibhav R Deshpande (SIRO Clinpharm Pvt Ltd) provided writing assistance and Dr Wendy P Battisti (Janssen Research & Development, LLC) provided additional editorial support and reviewed this manuscript. This study was funded by Janssen Research & Development, LLC. The sponsor also provided a formal review of this manuscript.
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![Risk analysis for VFDs.\
**Notes:** RR for VFDs between the topiramate group (all dose groups combined) and placebo group was not significant. 95% CI (0.78, 2.91).\
**Abbreviations:** CI, confidence interval; RR, relative risk; VFDs, visual field defects.](opth-11-983Fig1){#f1-opth-11-983}

###### 

TEAEs suggestive of retinal damage reported in approved indication studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                           Placebo\                                             All TPM\
                                                           N (%)                                                N (%)
  -------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------
  **Adjunctive epilepsy trials**                                                                                

  DB phase: 100--400, 600--1,000 mg/day, 5--25 mg/kg/day   (N=570)                                              (N=1,099)

   Patients with retinal damage TEAEs                      0                                                    5 (0.5)

    Scotoma                                                0                                                    1 (0.1)

    Tunnel vision                                          0                                                    1 (0.1)

    VFD                                                    0                                                    3 (0.3)

  OL phase                                                 (N=264)[a](#tfn1-opth-11-983){ref-type="table-fn"}   (N=2,262)[a](#tfn1-opth-11-983){ref-type="table-fn"}

   Patients with retinal damage TEAEs                      0                                                    12 (0.5)

    Blindness                                              0                                                    1 (\<0.1)

    Optic atrophy                                          0                                                    4 (0.2)

    Papillophlebitis                                       0                                                    1 (\<0.1)

    Retinal hemorrhage                                     0                                                    1 (\<0.1)

    Retinal vein occlusion                                 0                                                    1 (\<0.1)

    VFD                                                    0                                                    4 (0.2)

  **Monotherapy epilepsy trials**                                                                               

  DB phase: 50, 100, 200, 400,                             --                                                   (N=1,365)

  500 mg/day                                                                                                    

   Patients with retinal damage TEAEs                                                                           10 (0.7)

    Retinal hemorrhage                                                                                          1 (0.1)

    Scotoma                                                                                                     5 (0.4)

    VFD                                                                                                         4 (0.3)

  OL phase                                                 --                                                   (N=708)[b](#tfn2-opth-11-983){ref-type="table-fn"}

   Patients with retinal damage TEAEs                                                                           5 (0.7)

    Blindness                                                                                                   1 (0.1)

    Macular degeneration                                                                                        1 (0.1)

    Retinal hemorrhage                                                                                          1 (0.1)[d](#tfn4-opth-11-983){ref-type="table-fn"}

    Scotoma                                                                                                     3 (0.4)

    VFD                                                                                                         1 (0.1)

  **Migraine prophylaxis trials**                                                                               

  DB phase: 50, 100, 200 mg/day, 2--3 mg/kg/day            (N=1,264)                                            (N=2,215)

   Patients with retinal damage TEAEs                      1 (0.1)                                              7 (0.3)

    Retinal tear                                           1 (0.1)                                              0

    Scotoma                                                0                                                    1 (\<0.1)

    VFD                                                    0                                                    6 (0.3)

  OL phase                                                 (N=492)[c](#tfn3-opth-11-983){ref-type="table-fn"}   (N=2,258)[c](#tfn3-opth-11-983){ref-type="table-fn"}

   Patients with retinal damage TEAEs                      2 (0.4)                                              5 (0.2)

    Blindness                                              0                                                    1 (\<0.1)

    Retinal degeneration                                   0                                                    1 (\<0.1)

    Retinal vein occlusion                                 0                                                    1 (\<0.1)[d](#tfn4-opth-11-983){ref-type="table-fn"}

    Scotoma                                                0                                                    1 (\<0.1)

    Tunnel vision                                          0                                                    1 (\<0.1)

    VFD                                                    2 (0.4)                                              0
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Placebo group: patients who received placebo in DB phase but were switched to TPM during OL phase. TPM group: patients who received TPM during the DB phase and OL phase.

All patients received TPM during the OL phase. TPM: patients who were randomized to an active control during DB phase.

Placebo group: patients who received placebo in DB phase but were switched to TPM during OL phase. TPM group: patients who received TPM or an active comparator during the DB phase and who either remained on TPM or were switched from active control to TPM during the OL phase.

Serious TEAEs.

**Abbreviations:** DB, double-blind; OL, open-label; TEAE, treatment-emergent adverse event; TPM, topiramate; VFD, visual field defect.

###### 

TEAEs suggestive of retinal damage reported in investigational indication studies

                                                 Placebo N (%)                                        All TPM N (%)
  ---------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  **Bipolar disorder**                                                                                
  DB phase: ≤200, \>200--400, 500--600 mg/day    (N=630)                                              (N=892)
   Patients with retinal damage TEAEs            0                                                    2 (0.2)
    Retinal degeneration                         0                                                    1 (0.1)
    VFD                                          0                                                    1 (0.1)
  OL phase                                       (N=261)[a](#tfn6-opth-11-983){ref-type="table-fn"}   (N=436)[a](#tfn6-opth-11-983){ref-type="table-fn"}
   Patients with retinal damage TEAEs            0                                                    1 (0.2)
    Vitreous hemorrhage                          0                                                    1 (0.2)
  **Binge eating disorder**                                                                           
  DB phase: 200, 400 mg/day                      (N=202)                                              TPM 400 mg/day
                                                                                                      (N=202)
   Patients with retinal damage TEAEs            0                                                    1 (0.5)
    VFDs                                         0                                                    1 (0.5)
  **Diabetic peripheral neuropathy**                                                                  
  DB phase: 100, 200, 400 mg/day                 (N=531)                                              (N=1,140)
   Patients with retinal damage TEAEs            6 (1.1)                                              9 (0.8)
    Optic atrophy                                1 (0.2)                                              0
    Optic nerve disorder                         0                                                    1 (0.1)
    Retinal detachment                           2 (0.4)                                              0
    Retinal hemorrhage                           2 (0.4)                                              1 (0.1)
    Retinal infarction                           0                                                    1 (0.1)
    Retinal tear                                 0                                                    1 (0.1)
    Retinopathy                                  0                                                    2 (0.2)
    Scotoma                                      0                                                    1 (0.1)
    Vitreous adhesions                           0                                                    1 (0.1)
    Vitreous hemorrhage                          2 (0.4)                                              0
    VFD                                          0                                                    1 (0.1)
  OL phase                                       (N=357)[b](#tfn7-opth-11-983){ref-type="table-fn"}   (N=574)[b](#tfn7-opth-11-983){ref-type="table-fn"}
   Patients with retinal damage TEAEs            6 (1.7)                                              7 (1.2)
    Macular edema                                1 (0.3)                                              0
    Retinal detachment                           1 (0.3)                                              1 (0.2)[c](#tfn8-opth-11-983){ref-type="table-fn"}
    Retinal hemorrhage                           2 (0.6)                                              1 (0.2)
    Retinopathy                                  2 (0.6)                                              4 (0.7)
    Tunnel vision                                0                                                    1 (0.2)
  **Obesity**                                                                                         
  DB phase: \<100, 100--200, \>200--400 mg/day   (N=1,373)                                            (N=3,164)
   Patients with retinal damage TEAEs            5 (0.4)                                              9 (0.3)
    Macular degeneration                         1 (0.1)                                              0
    Retinal disorder                             1 (0.1)                                              0
    Retinal hemorrhage                           1 (0.1)                                              1 (\<0.1)
    Scotoma                                      0                                                    1 (\<0.1)
    Tunnel vision                                0                                                    3 (0.1)
    VFD                                          2 (0.1)                                              4 (0.1)

**Notes:**

Placebo group: patients who received placebo in DB phase but were switched to TPM during OL phase. TPM group: patients who received TPM or an active comparator during the DB phase and who either remained on TPM or were switched from active control to TPM during the OL phase.

Placebo group: patients who received placebo in DB phase but were switched to TPM during the OL phase. TPM group: patients who received TPM during the DB phase and OL phase.

Serious TEAE.

**Abbreviations:** DB, double-blind; OL, open-label; TEAE, treatment-emergent adverse event; TPM, topiramate; VFDs, visual field defects.

###### 

Patient demographics, seriousness, latency, and reversibility for patients of VFD reported with topiramate treatment

  Characteristics                                       Number of patients N=96
  ----------------------------------------------------- -------------------------
  Sex                                                   
   Men                                                  25
   Women                                                66
   Not reported                                         5
  Age group (years)                                     
   ≤17                                                  8
   18--35                                               26
   36--50                                               30
   51--64                                               13
   ≥65                                                  5
   Not reported                                         14
  Indication (≥2 patients)                              
   Epilepsy                                             24
   Migraine prophylaxis                                 15
   Migraine                                             12
   Convulsion                                           5
   Bipolar disorder                                     4
   Headache                                             3
   Neuralgia                                            3
   Convulsion prophylaxis                               2
   Partial seizures                                     2
   Unknown                                              11
  Seriousness                                           
   Serious                                              64
   Nonserious                                           32
  Latency[a](#tfn10-opth-11-983){ref-type="table-fn"}   
   \<7 days                                             8
   1 week to 1 month                                    19
   \>1 month to 3 months                                14
   \>3 months to 6 months                               10
   \>6 months to 1 year                                 3
   \>1 year to 5 years                                  13
   \>5 years                                            2
   Not reported                                         27
  Reversibility                                         
   Reversible                                           36
   Not reversible                                       20
   Unknown                                              40

**Note:**

Time course from the initial topiramate administration to the reported event of interest.

**Abbreviation:** VFD, visual field defect.
